PMID- 25446354 OWN - NLM STAT- MEDLINE DCOM- 20151231 LR - 20150105 IS - 1873-7544 (Electronic) IS - 0306-4522 (Linking) VI - 285 DP - 2015 Jan 29 TI - The effect of CA1 dopaminergic system in harmaline-induced amnesia. PG - 47-59 LID - S0306-4522(14)00959-2 [pii] LID - 10.1016/j.neuroscience.2014.11.012 [doi] AB - In the present study, the effects of bilateral injections of dopaminergic drugs into the hippocampal CA1 regions (intra-CA1) on harmaline-induced amnesia were examined in male mice. A one-trial step-down passive avoidance task was used for the assessment of memory retention in adult male mice. Pre-training intra-peritoneal (i.p.) administration of harmaline (1 mg/kg) induced impairment of memory retention. Moreover, intra-CA1 administration of dopamine D1 receptor antagonist, SCH23390 (0.02 mug/mouse), dopamine D1 receptor agonist, SKF38393 (0.5 mug/mouse), dopamine D2 receptor antagonist, sulpiride (1 mug/mouse) and dopamine D2 receptor agonist, quinpirole (0.25 and 0.5 mug/mouse) suppressed the learning of a single-trial passive avoidance task. Also, pre-training intra-CA1 injection of subthreshold doses of SCH23390 (0.001 mug/mouse) or sulpiride (0.25 mug/mouse) with the administration of harmaline (1 mg/kg, i.p.) reversed impairment of memory formation. However, pre-training intra-CA1 injection of SKF38393 (0.1 mug/mouse) or quinpirole (0.1 mug/mouse) increased pre-training harmaline (0.25 and 0.5 mg/kg, i.p.)-induced retrieval impairment. Moreover, SKF Ca blocker (SKF) (0.01 mug/mouse) decrease the amnesia induced by harmaline (1 mg/kg), while co-administration of SKF (0.01 mug/mouse)/sulpiride (0.25 mug/mouse) or SCH23390 (0.001 mug/mouse)/sulpiride (0.25 mug/mouse) potentiate amnesia caused by harmaline. These findings implicate the involvement of CA1 dopaminergic mechanism in harmaline-induced impairment of memory acquisition. CI - Copyright (c) 2014 IBRO. Published by Elsevier Ltd. All rights reserved. FAU - Nasehi, M AU - Nasehi M AD - School of Advanced Sciences in Medicine, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran; Institute for Cognitive Science Studies (ICSS), Tehran, Iran. Electronic address: Nasehi@iricss.org. FAU - Ketabchi, M AU - Ketabchi M AD - Department of Biology, Faculty of Basic Sciences, Northern Branch, Islamic Azad University, Tehran, Iran. FAU - Khakpai, F AU - Khakpai F AD - Institute for Cognitive Science Studies (ICSS), Tehran, Iran. FAU - Zarrindast, M-R AU - Zarrindast MR AD - School of Advanced Sciences in Medicine, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran; Institute for Cognitive Science Studies (ICSS), Tehran, Iran; Department of Pharmacology School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran; School of Cognitive Sciences, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran. Electronic address: zarinmr@ams.ac.ir. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141115 PL - United States TA - Neuroscience JT - Neuroscience JID - 7605074 RN - 0 (Benzazepines) RN - 0 (Dopamine Agonists) RN - 0 (Dopamine Antagonists) RN - 0 (Monoamine Oxidase Inhibitors) RN - 0 (Receptors, Dopamine D1) RN - 0 (Receptors, Dopamine D2) RN - 0 (SCH 23390) RN - 67287-49-4 (2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine) RN - 7MNE9M8287 (Sulpiride) RN - CN58I4TOET (Harmaline) RN - VTD58H1Z2X (Dopamine) SB - IM MH - 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology MH - Amnesia/*chemically induced/drug therapy/metabolism MH - Animals MH - Avoidance Learning/drug effects/physiology MH - Benzazepines/pharmacology MH - CA1 Region, Hippocampal/*drug effects/metabolism MH - Dopamine/metabolism MH - Dopamine Agonists/*pharmacology MH - Dopamine Antagonists/*pharmacology MH - Harmaline/*toxicity MH - Male MH - Memory/drug effects/physiology MH - Mice MH - Monoamine Oxidase Inhibitors/*toxicity MH - Receptors, Dopamine D1/metabolism MH - Receptors, Dopamine D2/metabolism MH - Sulpiride/pharmacology OTO - NOTNLM OT - CA1 OT - dopamine OT - harmaline OT - passive avoidance memory OT - step-down EDAT- 2014/12/03 06:00 MHDA- 2016/01/01 06:00 CRDT- 2014/12/03 06:00 PHST- 2014/07/23 00:00 [received] PHST- 2014/10/31 00:00 [revised] PHST- 2014/11/04 00:00 [accepted] PHST- 2014/12/03 06:00 [entrez] PHST- 2014/12/03 06:00 [pubmed] PHST- 2016/01/01 06:00 [medline] AID - S0306-4522(14)00959-2 [pii] AID - 10.1016/j.neuroscience.2014.11.012 [doi] PST - ppublish SO - Neuroscience. 2015 Jan 29;285:47-59. doi: 10.1016/j.neuroscience.2014.11.012. Epub 2014 Nov 15.